Mechanistic insights into factor VIII inhibitor formation and eradication

对因子 VIII 抑制剂形成和根除的机制见解

基本信息

  • 批准号:
    10641791
  • 负责人:
  • 金额:
    $ 15.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-06-01 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT This K99 Career Pathway to Independence in Blood Science Award details a five-year training program to advance Dr. Bhavya Doshi’s career goal of becoming an independent translational physician-scientist in coagulation. The proposed application combines approaches using tissue culture and animal models with investigations using patient samples to address the current limitations in the understanding of the immune response to factor VIII (FVIII). Dr. Doshi’s career development and training objectives are geared to foster this research proposal and her overall career goal of understanding basic mechanisms that drive disease to develop targeted treatment and prevention strategies. During the award period, Dr. Doshi will engage with a robust team of scientists in hemostasis and immunology to build her immunologic and translational research skills, learn genomic skills necessary for her future career aspirations, and continue to develop her expertise in coagulation and inhibitors. Under the guidance of her mentors, Dr. Rodney Camire and Dr. Michael Milone, these training objectives will be met by a combination of didactic course work and workshops, participation in seminar series, hands-on research experience, and mentoring by her advisory committee. Her advisory committee is composed of world-renowned scientists with extensive mentoring experience and diverse and complementary scientific expertise. They are all versed in bringing basic research findings to the bedside. Hemophilia A (HA) is caused by a mutation in the F8 gene leading to dysfunction or deficiency of coagulation FVIII. The development of neutralizing antibodies (“inhibitors”) to FVIII is the leading cause of morbidity and mortality in patients with HA. Dr. Doshi’s preliminary studies in HA patients and mice are the first to support that the cytokine B cell activating factor (BAFF) is potentially a biomarker and/or regulator of the FVIII immune response. This proposal seeks to probe basic mechanisms in FVIII-specific B cell generation and how BAFF contributes to this humoral response in order to leverage these findings for therapeutic application. Aim 1 seeks to determine the location, kinetics, and types of B cell responses to FVIII in mice by using a novel method to identify FVIII-specific B cells and subsequently determine what happens to this compartment with immunomodulatory strategies, including anti-BAFF. As BAFF is both systemically and locally produced by fibroblast cells and hematopoietically-derived immune cells, respectively, Aim 2 investigates the source of BAFF and its effect on the T cell response to FVIII. Finally, Aim 3 assesses whether genetic drivers of cytokine levels for BAFF or T helper cytokines drive phenotypic changes in T and B cell subsets that lead to inhibitor generation and/or persistence in HA patients. Together, these studies will inform the immune compartments that are critical to the FVIII immune response and establish the preclinical data to translate anti-BAFF therapy to the clinics. The research and career objectives in this proposal will bolster Dr. Doshi’s research repertoire to enable her transition to an independent physician scientist focused on blood disorders, specifically hemophilia.
项目总结/摘要 这个K99职业道路独立血液科学奖详细介绍了一个为期五年的培训计划, 推进Bhavya Doshi博士的职业目标,成为一名独立的翻译医生,科学家, 凝血所提出的应用结合了使用组织培养和动物模型的方法, 使用患者样本进行研究,以解决目前对免疫缺陷的理解存在的局限性。 对凝血因子VIII(FVIII)的反应。Doshi博士的职业发展和培训目标旨在促进这一点 她的研究计划和她的总体职业目标是了解疾病的基本机制, 制定有针对性的治疗和预防战略。在颁奖期间,Doshi博士将与一位 强大的止血和免疫学科学家团队,以建立她的免疫学和转化研究 技能,学习她未来职业抱负所需的基因组技能,并继续发展她在以下方面的专业知识: 凝血和抑制剂。在她的导师Rodney Camire博士和Michael Milone博士的指导下, 这些培训目标将通过教学课程和讲习班相结合的方式来实现, 研讨会系列,实践研究经验,并由她的顾问委员会指导。她的咨询 委员会由世界知名的科学家组成,他们具有丰富的指导经验, 补充科学知识。他们都擅长将基础研究成果带到床边。 血友病A(HA)是由F8基因突变引起的,导致凝血功能障碍或缺陷 第VIII节。FVIII中和抗体(“抑制剂”)的产生是发病的主要原因, HA患者的死亡率。Doshi博士在HA患者和小鼠中的初步研究首次支持了 细胞因子B细胞活化因子(BAFF)可能是FVIII免疫抑制的生物标志物和/或调节剂, 反应该提议试图探索FVIII特异性B细胞生成的基本机制以及BAFF如何在细胞中表达。 有助于这种体液反应,以便将这些发现用于治疗应用。要求1 试图通过使用一种新的方法来确定小鼠中B细胞对FVIII反应的位置、动力学和类型。 一种鉴定FVIII特异性B细胞并随后确定该隔室发生了什么的方法, 免疫调节策略,包括抗BAFF。由于BAFF是系统性和本地生产的, 成纤维细胞和造血来源的免疫细胞,目的2调查的来源, BAFF及其对T细胞对FVIII应答的影响。最后,目标3评估细胞因子的遗传驱动因素是否 BAFF或T辅助细胞因子的水平驱动T和B细胞亚群的表型变化, 在HA患者中产生和/或持续。总之,这些研究将告知免疫区室 对FVIII免疫应答至关重要,并建立临床前数据以转化抗BAFF治疗 去诊所本提案中的研究和职业目标将支持Doshi博士的研究曲目, 使她成为一名独立的医生科学家,专注于血液疾病,特别是血友病。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bhavya Sharad Doshi其他文献

Bhavya Sharad Doshi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bhavya Sharad Doshi', 18)}}的其他基金

Mechanistic insights into factor VIII inhibitor formation and eradication
对因子 VIII 抑制剂形成和根除的机制见解
  • 批准号:
    10413819
  • 财政年份:
    2021
  • 资助金额:
    $ 15.52万
  • 项目类别:
Mechanistic insights into factor VIII inhibitor formation and eradication
对因子 VIII 抑制剂形成和根除的机制见解
  • 批准号:
    10117521
  • 财政年份:
    2021
  • 资助金额:
    $ 15.52万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 15.52万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.52万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 15.52万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.52万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 15.52万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.52万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 15.52万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 15.52万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 15.52万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.52万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了